Propella Therapeutics, Pittsboro firm with 5 employees, sold for $175M

As part of the acquisition, Astellas will acquire Propella's lead asset, a potential treatment for metastatic prostate cancer. Astellas, which opened a $100 million plant in North Carolina in 2022, has run afoul of both U.S. and British authorities in recent years.

Previous KC biotech startup partners with Oral Biolife to launch periodontal treatment for pets
Next How much did Novant Health execs make in 2022? CEO gets nearly 19% raise